DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

In a report released on December 16, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom, with a price target of $99.00. The company’s shares closed yesterday at $66.37.

DexCom, Inc. ( NASDAQ:DXCM ) shareholders should be happy to see the share price up 12% in the last month. But ...

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 ...

Fintel reports that on December 17, 2025, Mizuho maintained coverage of DexCom (NasdaqGS:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 33.91% Upside As of December 6, 2025, ...

Mizuho raised the firm’s price target on DexCom (DXCM) to $78 from $75 and keeps an Outperform rating on the shares. The firm ...

Investors encouraged to join DexCom class action lawsuit. Allegations include unapproved design changes to G6/G7 glucose monitors, FDA warning, and health risks. Deadline Dec 26, 2025.

All four Irish provinces are back in action this week across the Investec Champions and Challenge Cup pool stages. Here's everything you need to know ahead of this weekend's games.

Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Despite these positive results, BTIG lowered its price target for DexCom to $85 from $109, maintaining a Buy rating due to growth concerns. Similarly, Canaccord Genuity reduced its price target to $99 ...